WCN26-6282 A case of successful treatment of severe ANCA-associated vasculitis with diverse neurological symptoms using a steroid reduction regimen combined with Avacopan and Rituximab

Read full text Summarise with VIRAT
Authors: Mana Fujimoto, Yu Tateishi, Yasuko Miyamoto, Satoshi Yamaoka, Makoto Hashimoto, Yusuke Fukuda, Yuki Hayakawa, Masahito Imanishi
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

In recent years, steroid reduction regimens combined with other immunosuppressants have been proposed for ANCA-associated vasculitis (AVA) to prevent side effects. The efficacy of Avacopan, one of the candidate combination drugs, for neurological disorders associated with AVA is not well known.

Fields of Study & Subjects

Vasculitis and related conditions Renal Diseases and Glomerulopathies Complement system in diseases

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
106262–106262
Publication date
25 March 2026
Language
EN